Yogan A Patel, Partner at MHA and Head of MHA’s Pharma, Life Science and Med-Tech sector group examines the investment landscape for early-stage biotech companies in the UK and further afield. It is well recognised by both investors and government that the UK has huge strengths in biotechnology. Investment opportunities offer both lucrative returns […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!